$9346 | SAVE $1,649 | Single User
$18692 | SAVE $3,298 | Site License
$28037 | SAVE $4,948 | Enterprise License

PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025
[Published by Global Data]

Published by Global Data: 01 May 2016 | 27045 | In Stock
Related Topics: Heart Failure , Novartis

Introduction

PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025

Summary

GlobalData estimates sales of Heart Failure (HF) therapeutics to be approximately .2B across the 7MM in 2015, encompassing the US, 5EU, and Japan. The HF market will grow at a strong CAGR of 13.5% over the forecast period, reaching sales of .5B by 2025. The 7MM chronic HF market size in 2015 was .1B, and is expected to increase to .1B by 2025 at a CAGR of 12.7%. The US was the largest market for chronic HF therapies, contributing 61.2% of total sales in the base year. GlobalData expects uptake of Novartis’ Entresto to be the strongest driver of the chronic HF and total HF markets in the 7MM, reaching peak sales of .9B in 2022. The acute HF market is expected to increase from just 8.1M in 2015 to .5B in 2025, at a CAGR of 23.0%. Japan dominated the acute HF market in the base year, 2015, accounting for 86.0% of market share. However, with the launch of several acute HF add-on therapies in the forecast period, the US will take over as the acute HF market leader, contributing 68.7% of sales to the acute HF market by 2025.

Highlights

Key Questions Answered

- The level of unmet needs in the HF market is significantly high. Will the pipeline drugs fulfil these unmet needs of the market? Key Opinion Leaders (KOLs) interviewed by GlobalData provide insights and highlight opportunities for drug developers.

- The HF market is crowded with cheap, generic, “me-too” drugs, making it a particularly difficult market to penetrate. The current late-stage pipeline consists of several chronic HF therapies, and three novel acute HF therapies. How will the market be impacted by the launch of these drugs? Which of the marketed and pipeline drugs will have the highest peak sales at the highest CAGR, and why?

- Will Entresto become the new standard-of-care in the chronic HF market? What are the main barriers a new therapy faces when entering the HF market?

Key Findings

- The major drivers for growth across the 7MM in the HF market during the forecast period will be the launch of the first-in-class angiotensin receptor blocker/neprilysin inhibitor (ARNi), Entresto, marketed by Novartis, as well as the launches of two acute HF therapies, Cardiorentis’ ularitide and Novartis’ serelaxin.

- KOLs interviewed by GlobalData opined that Entresto has potential to replace ACE inhibitors as the first-line therapy for HF, however they expect this to occur towards the end of the forecast period.

- In other interviews, KOLs highlighted that the greatest unmet need in the HF disease space is the need to develop efficacious therapies for HF with preserved ejection fraction (HF-PEF) and acute HF.

- High cost of new drugs and the reluctance of cardiologists to prescribe these new drugs are the major barriers for growth in the HF market during the forecast period.

Scope

- Overview of HF, both chronic and acute, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

- Annualized HF therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the chronic and acute HF therapeutics markets.

- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

- Analysis of the current and future market competition in the global HF therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.

- Develop business strategies by understanding the trends shaping and driving the HF therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HF therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Track drug sales in the 7MM HF therapeutics market from 2015-2025.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents
for PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025 [Published by Global Data]

  • 1 Table of Contents

    1 Table of Contents 10

    1.1 List of Tables 17

    1.2 List of Figures 22

    2 Introduction 24

    2.1 Catalyst 24

    2.2 Related Reports 24

    3 Disease Overview 25

    3.1 Etiology and Pathophysiology 25

    3.1.1 Etiology 25

    3.2 Classification and Staging Systems 32

    3.3 Symptoms 33

    3.4 Prognosis 34

    3.5 Quality of Life 35

    4 Epidemiology 37

    4.1 Disease Background 37

    4.2 Risk Factors and Comorbidities 38

    4.3 Global Trends 40

    4.3.1 US 40

    4.3.2 5EU 41

    4.3.3 Japan 42

    4.4 Forecast Methodology 42

    4.4.1 Sources Used 45

    4.4.2 Forecast Assumptions and Methods 48

    4.4.3 Sources Not Used 63

    4.5 Epidemiological Forecast for HF (2015-2025) 63

    4.5.1 Diagnosed Incident Cases 63

    4.5.2 Diagnosed Prevalent Cases 77

    4.6 Discussion 89

    4.6.1 Epidemiological Forecast Insight 89

    4.6.2 Limitations of the Analysis 89

    4.6.3 Strengths of the Analysis 90

    5 Disease Management 91

    5.1 Diagnosis and Treatment Overview 91

    5.1.1 Diagnosis 91

    5.1.2 Treatment Guidelines and Leading Prescribed Drugs 94

    5.1.3 Medical Devices 99

    5.1.4 Clinical Practice 100

    5.2 US 106

    5.3 5EU 108

    5.4 Japan 112

    6 Competitive Assessment 115

    6.1 Overview 115

    6.2 Drug Profiles 116

    6.2.1 Angiotensin-Converting Enzyme Inhibitors 116

    6.2.2 Angiotensin Receptor Blockers 122

    6.2.3 Entresto (sacubitril + valsartan) 126

    6.2.4 Diuretics 141

    6.2.5 Beta Blockers 146

    6.2.6 Procoralan (ivabradine) 150

    6.2.7 Mineralocorticoid Receptor Antagonists 158

    6.2.8 Digoxin 162

    6.2.9 Pharmacological Therapies for Acute HF 165

    7 Unmet Needs and Opportunities 168

    7.1 Overview 168

    7.1.1 Acute HF - Target Opportunity Profile 170

    7.1.2 HF with Preserved Ejection Fraction - Target Opportunity Profile 173

    7.1.3 HF with Reduced Ejection Fraction - Target Opportunity Profile 176

    7.2 Lack of Therapies for HF with Preserved Ejection Fraction Patients 181

    7.2.1 Unmet Need 181

    7.2.2 Gap Analysis 182

    7.2.3 Opportunity 183

    7.3 Lack of Therapies for Acute HF 183

    7.3.1 Unmet Need 183

    7.3.2 Gap analysis 184

    7.3.3 Opportunity 185

    7.4 Lack of Therapies for Acute HF Patients Experiencing Diuretic Resistance 186

    7.4.1 Unmet Need 186

    7.4.2 Gap Analysis 187

    7.4.3 Opportunity 188

    7.5 Lack of Therapies for Patients with Renal Impairment 188

    7.5.1 Unmet Need 188

    7.5.2 Gap Analysis 189

    7.5.3 Opportunity 189

    7.6 Treatment of Patients with Multiple Comorbidities 190

    7.6.1 Unmet Need 190

    7.6.2 Gap Analysis 191

    7.6.3 Opportunity 191

    7.7 Enhanced Diagnosis and Preventative Therapies for Patients at Risk of Developing HF 192

    7.7.1 Unmet Need 192

    7.7.2 Gap Analysis 193

    7.7.3 Opportunity 194

    7.8 Conducting Clinical Trials in Cohorts of Japanese Patients 195

    7.8.1 Unmet Need 195

    7.8.2 Gap Analysis 196

    7.8.3 Opportunity 196

    7.9 Use of Optimal Doses of HF Therapies 197

    7.9.1 Unmet Need 197

    7.9.2 Gap Analysis 198

    7.9.3 Opportunity 199

    7.10 Patient Compliance 199

    7.10.1 Unmet Need 199

    7.10.2 Gap Analysis 200

    7.10.3 Opportunity 201

    7.11 Early Detection and Treatment of Patients with Worsening Chronic HF 201

    7.11.1 Unmet Need 201

    7.11.2 Gap Analysis 202

    7.11.3 Opportunity 203

    7.12 Dynamic Management of Patients with HF 203

    7.12.1 Unmet Need 203

    7.12.2 Gap Analysis 205

    7.12.3 Opportunity 205

    7.13 Options for Advanced HF Patients Who Are Unable to Receive a Heart Transplant 206

    7.13.1 Unmet Need 206

    7.13.2 Gap Analysis 207

    7.13.3 Opportunity 207

    8 Pipeline Assessment 208

    8.1 Overview 208

    8.2 Promising Drugs in Late-Stage Clinical Development 210

    8.2.1 Serelaxin 212

    8.2.2 Ularitide 221

    8.2.3 Omecamtiv Mecarbil 229

    8.2.4 Vericiguat 238

    8.2.5 Finerenone 245

    8.2.6 Neucardin 251

    8.2.7 Revatio 255

    8.3 Promising Drugs in Early Stage Development 259

    8.3.1 CXL-1427 259

    8.3.2 Istaroxime 260

    8.3.3 Perhexiline Maleate 260

    8.3.4 TRV-027 261

    8.4 Other Drugs in Development 261

    9 Current and Future Players 263

    9.1 Overview 263

    9.2 Trends in Corporate Strategy 265

    9.3 Company Profiles 266

    9.3.1 Novartis 266

    9.3.2 Les Laboratoires Servier 269

    9.3.3 Cardiorentis 271

    9.3.4 Bayer (and Merck & Co.) 272

    9.3.5 Cytokinetics 274

    10 Market Outlook 276

    10.1 Global Markets 276

    10.1.1 Forecast 276

    10.1.2 Drivers and Barriers - Global Issues 281

    10.2 US 285

    10.2.1 Forecast 285

    10.2.2 Key Events 289

    10.2.3 Drivers and Barriers 290

    10.3 France 291

    10.3.1 Forecast 291

    10.3.2 Key Events 295

    10.3.3 Drivers and Barriers 296

    10.4 Germany 297

    10.4.1 Forecast 297

    10.4.2 Key Events 300

    10.4.3 Drivers and Barriers 301

    10.5 Italy 302

    10.5.1 Forecast 302

    10.5.2 Key Events 305

    10.5.3 Drivers and Barriers 306

    10.6 Spain 307

    10.6.1 Forecast 307

    10.6.2 Key Events 310

    10.6.3 Drivers and Barriers 311

    10.7 UK 312

    10.7.1 Forecast 312

    10.7.2 Key Events 315

    10.7.3 Drivers and Barriers 316

    10.8 Japan 317

    10.8.1 Forecast 317

    10.8.2 Key Events 321

    10.8.3 Drivers and Barriers 321

    11 Appendix 324

    11.1 Bibliography 324

    11.2 Abbreviations 356

    11.3 Methodology 364

    11.4 Forecasting Methodology 364

    11.4.1 Diagnosed Prevalent Chronic HF 364

    11.4.2 Diagnosed Incidence of Acute HF 365

    11.4.3 Percent Drug-Treated Patients 365

    11.4.4 Treatment of HF with Reduced Ejection Fraction Versus HF with Preserved Ejection Fraction 365

    11.4.5 Drugs Included in Each Therapeutic Class 365

    11.4.6 Launch and Patent Expiry Dates 366

    11.4.7 General Pricing Assumptions 367

    11.4.8 Individual Drug Assumptions 368

    11.4.9 Generic Erosion 373

    11.4.10 Pricing of Pipeline Agents 373

    11.5 Key Opinion Leaders Included in This Study 375

    11.6 Payers Included in This Study 377

    11.7 High-Prescribing Physician Survey 378

    11.8 About the Authors 379

    11.8.1 Author 379

    11.8.2 Contributing Author 379

    11.8.3 Therapy Area Director 379

    11.8.4 Epidemiologist 380

    11.8.5 Global Director of Therapy Analysis and Epidemiology 380

    11.8.6 Global Head of Healthcare 381

    11.9 About GlobalData 382

    11.10 Disclaimer 382

List Of Tables
in PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025 [Published by Global Data]

1.1 List of Tables

Table 1: Leading Causes of HF 27

Table 2: A Summary of the Compensatory Mechanisms in HF 28

Table 3: The Two Main Classification Systems in HF 33

Table 4: Typical Symptoms of HF 34

Table 5: Risk Factors and Comorbidities for HF 39

Table 6: NYHA Functional Classes I-IV 44

Table 7: ACCF/AHA Stages A, B, C, and D 44

Table 8: 7MM, Sources of Epidemiological Data Used for the Forecast of HF Diagnosed Incident Cases 45

Table 9: 7MM, Sources of Epidemiological Data Used for the Forecast of Chronic HF Diagnosed Prevalent Cases 46

Table 10: 7MM, Sources of Epidemiological Data Used for the Classification of Diagnosed Prevalent Cases of Chronic HF According to the NYHA Functional Classes I-IV 47

Table 11: 7MM, Sources of Epidemiological Data Used for Forecast of HF Diagnosed Incident Cases of Acute HF Hospitalizations 48

Table 12: 7MM, Sources Not Used in Epidemiological Analysis of HF 63

Table 13: 7MM, Diagnosed Incident Cases of HF, Ages ≥45 Years, Both Sexes, N, 2015-2025 64

Table 14: 7MM, Age-Specific Diagnosed Incident Cases of HF, Both Sexes, N (Row %), 2015 66

Table 15: 7MM, Sex-Specific Diagnosed Incident Cases of HF, Ages ≥45 Years, N (Row %), 2015 68

Table 16: 7MM, Diagnosed Incident Cases of Acute HF Hospitalizations, Ages ≥45 Years, Both Sexes, N, 2015-2025 73

Table 17: 7MM, Readmissions (Within Three Months) Post-Discharge After Acute HF Hospitalization Among Diagnosed Incident Cases of Acute HF, Ages ≥45 Years, Both Sexes, N, 2015-2025 75

Table 18: 7MM, Diagnosed Prevalent Cases of Chronic HF, Ages ≥45 Years, Both Sexes, N, 2015-2025 78

Table 19: 7MM, Age-Specific Diagnosed Prevalent Cases of Chronic HF, Both Sexes, N (Row %), 2015 80

Table 20: 7MM, Sex-Specific Diagnosed Prevalent Cases of Chronic HF, Ages ≥45 Years, N (Row %), 2015 82

Table 21: Guideline Recommended Tests for the Diagnosis of HF 92

Table 22: Common Factors that Precipitate Acute HF 94

Table 23: Treatment Guidelines for HF 95

Table 24: Comparison of the ACCF/AHA and NYHA HF Classification Systems 96

Table 25: Most Prescribed Drugs for HF by Class in the Global Markets, 2015 97

Table 26: Country Profile for HF - US 107

Table 27: Country Profile for HF - 5EU 110

Table 28: Country Profile for HF - Japan 113

Table 29: Efficacy of Enalapril 118

Table 30: Efficacy of Perindopril 120

Table 31: Global Sales Forecasts ($M) for ACE inhibitors, 2015-2025 122

Table 32: Global Sales Forecasts ($M) for ARBs, 2015-2025 126

Table 33: Product Profile - Entresto 133

Table 34: Efficacy of Entresto 134

Table 35: Safety of Entresto 136

Table 36: Entresto SWOT Analysis, 2015 138

Table 37: Global Sales Forecasts ($M) for Entresto, 2015-2025 141

Table 38: Global Sales Forecasts ($M) for Diuretics in the Chronic HF Market, 2015-2025 145

Table 39: Global Sales Forecasts ($M) for Loop Diuretics in the Acute HF Market, 2015-2025 145

Table 40: Global Sales Forecasts ($M) for Beta Blockers, 2015-2025 150

Table 41: Product Profile - Ivabradine 153

Table 42: Efficacy of Ivabradine 154

Table 43: Ivabradine SWOT Analysis, 2015 156

Table 44: Global Sales Forecasts ($M) for Procoralan/Corlanor (ivabradine), 2015-2025 158

Table 45: Global Sales Forecasts ($M) for MRAs, 2015-2025 162

Table 46: Global Sales Forecasts ($M) for Digoxin, 2015-2025 165

Table 47: Unmet Needs and Opportunities in HF 169

Table 48: Target Opportunity Profile for Acute HF 171

Table 49: Target Opportunity Profile for HF-PEF 175

Table 50: Target Opportunity Profile for HF-REF 178

Table 51: Chronic HF Comorbidities in the 7MM 192

Table 52: Comparison of Therapeutic Classes in Development for HF, 2015 212

Table 53: Product Profile - Serelaxin 215

Table 54: Efficacy of Serelaxin 217

Table 55: Serelaxin SWOT Analysis, 2015 220

Table 56: Global Sales Forecasts ($M) for Serelaxin, 2015-2025 221

Table 57: Product Profile - Ularitide 224

Table 58: Safety of Ularitide 226

Table 59: Ularitide SWOT Analysis, 2015 228

Table 60: Global Sales Forecasts ($M) for Ularitide, 2015-2025 229

Table 61: Product Profile - OM 232

Table 62: Efficacy of OM 233

Table 63: OM SWOT Analysis, 2015 236

Table 64: Global Sales Forecasts ($M) for OM (Chronic HF), 2015-2025 237

Table 65: Global Sales Forecasts ($M) for OM (Acute HF), 2015-2025 238

Table 66: Product Profile - Vericiguat 240

Table 67: Efficacy of Vericiguat 241

Table 68: Safety of Vericiguat 242

Table 69: Vericiguat SWOT Analysis, 2015 244

Table 70: Global Sales Forecasts ($M) for vericiguat, 2015-2025 245

Table 71: Product Profile - Finerenone 247

Table 72: Finerenone SWOT Analysis, 2015 250

Table 73: Product Profile - Neucardin 252

Table 74: Neucardin SWOT Analysis, 2015 255

Table 75: Product Profile - Revatio 256

Table 76: Efficacy of Revatio 257

Table 77: Revatio SWOT Analysis, 2015 259

Table 78: Drugs in Development, 2015 262

Table 79: Key Companies in the HF Market in the 7MM, 2015-2025 264

Table 80: Novartis’ HF Portfolio Assessment, 2015 268

Table 81: Serviers’ HF Portfolio Assessment, 2015 270

Table 82: Cardiorentis’ HF Portfolio Assessment, 2015 272

Table 83: Bayer’s HF Portfolio Assessment, 2015 274

Table 84: Cytokinetics’ HF Portfolio Assessment, 2015 275

Table 85: Global Sales Forecasts ($M) for Chronic HF, 2015-2025 277

Table 86: Global Sales Forecasts ($M) for Acute HF, 2015-2025 279

Table 87: HF Global Market - Drivers and Barriers, 2015-2025 281

Table 88: Sales Forecasts ($M) for HF in the US, 2015-2025 287

Table 89: Key Events Impacting Sales for HF in the US, 2015-2025 289

Table 90: US HF Market - Drivers and Barriers, 2015-2025 290

Table 91: Sales Forecasts ($M) for HF in France, 2015-2025 293

Table 92: Key Events Impacting Sales for HF in France, 2015-2025 295

Table 93: French HF market - Drivers and Barriers, 2015-2025 296

Table 94: Sales Forecasts ($M) for HF in Germany, 2015-2025 298

Table 95: Key Events Impacting Sales for HF in Germany, 2015-2025 300

Table 96: Germany HF market - Drivers and Barriers, 2015-2025 301

Table 97: Sales Forecasts ($M) for HF in Italy, 2015-2025 303

Table 98: Key Events Impacting Sales for HF in Italy, 2015-2025 305

Table 99: Italy HF market - Drivers and Barriers, 2015-2025 306

Table 100: Sales Forecasts ($M) for HF in Spain, 2015-2025 308

Table 101: Key Events Impacting Sales for HF in Spain, 2015-2025 310

Table 102: Spain HF market - Drivers and Barriers, 2015-2025 311

Table 103: Sales Forecasts ($M) for HF in the UK, 2015-2025 313

Table 104: Key Events Impacting Sales for HF in the UK, 2015-2025 315

Table 105: UK HF market - Drivers and Barriers, 2015-2025 316

Table 106: Sales Forecasts ($M) for HF in Japan, 2015-2025 318

Table 107: Key Events Impacting Sales for HF in Japan, 2015-2025 321

Table 108: Japan HF market - Drivers and Barriers, 2015-2025 321

Table 109: Key Launch Dates 366

Table 110: Key Patent Expiries 366

Table 111: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 378

List Of Figures, Charts and Diagrams
in PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025 [Published by Global Data]

1.2 List of Figures

Figure 1: RAAS Mechanism of Action 30

Figure 2: 7MM, Diagnosed Incident Cases of HF, Ages ≥45 Years, Both Sexes, N, 2015-2025 65

Figure 3: 7MM, Diagnosed Incident Cases of HF by Age Group, Both Sexes, N, 2015 67

Figure 4: 7MM, Sex-Specific Diagnosed Incident Cases of HF, Ages ≥45 Years, N, 2015 69

Figure 5: 7MM, Age-Standardized Diagnosed Incidence of HF (Cases per 100,000 Population), Ages ≥45 Years, by Sex, 2015 70

Figure 6: 7MM, Diagnosed Incident Cases of HF Segmented by EF, Ages ≥45 Years, Both Sexes, N, 2015 71

Figure 7: 7MM, Diagnosed Incident Cases of HF Segmented by Ventricular Dysfunction, Ages ≥45 Years, Both Sexes, N, 2015 72

Figure 8: 7MM, Diagnosed Incident Cases of Acute HF Hospitalizations, Ages ≥45 Years, Both Sexes, N, 2015-2025 73

Figure 9: 7MM, Diagnosed Incident Cases of Acute HF Hospitalizations, Ages ≥45 Years, Both Sexes, N, 2015 74

Figure 10: 7MM, Readmissions (Within Three Months) Post-Discharge After Acute HF Hospitalization Among Diagnosed Incident Cases of Acute HF, Ages ≥45 Years, Both Sexes, N, 2015-2025 76

Figure 11: 7MM, Hospital Length Of Stay For Acute HF Hospitalization, Ages ≥45 Years, Both Sexes, Days, 2015 77

Figure 12: 7MM, Diagnosed Prevalent Cases of Chronic HF, Ages ≥45 Years, Both Sexes, N, 2015-2025 79

Figure 13: 7MM, Age-Specific Diagnosed Prevalent Cases of Chronic HF, Both Sexes, N, 2015 81

Figure 14: 7MM, Sex-Specific Diagnosed Prevalent Cases of Chronic HF, Ages ≥45 Years, N, 2015 83

Figure 15: 7MM, Age-Standardized Diagnosed Prevalence of Chronic HF (%), Ages ≥45 Years, by Sex, 2015 84

Figure 16: 7MM, Diagnosed Prevalent Cases of Chronic HF Segmented by EF, Ages ≥45 Years, Both Sexes, N, 2015 85

Figure 17: 7MM, Diagnosed Prevalent Cases of Chronic HF Segmented by NYHA Classes, Ages ≥45 Years, Both Sexes, N, 2015 86

Figure 18: 7MM, Diagnosed Prevalent Cases of Chronic HF Segmented by ACCF/AHA Stages, Ages ≥45 Years, Both Sexes, N, 2015 87

Figure 19: 7MM, Prevalent Cases of Comorbidities Among Diagnosed Prevalent Cases of Chronic HF, Both Sexes, Ages ≥45 Years, N, 2015 88

Figure 20: HF treatment based on ACCF/AHA Stage 101

Figure 21: HF - Phase II-III Pipeline, 2015 210

Figure 22: Competitive Assessment of Late-Stage Pipeline Agents in HF, 2015-2025 211

Figure 23: Company Portfolio Gap Analysis in HF, 2015-2025 265

Figure 24: Global Sales for Chronic HF by Region, 2015-2025 278

Figure 25: Global Sales for Acute HF by Region, 2015-2025 280

Figure 26: Sales for Chronic HF in the US by Drug Class, 2015-2025 288

Figure 27: Sales for Acute HF in the US by Drug Class, 2025* 289

Figure 28: Sales for Chronic HF in France by Drug Class, 2015-2025 294

Figure 29: Sales for Acute HF in France by Drug Class, 2025* 295

Figure 30: Sales for Chronic HF in Germany by Drug Class, 2015-2025 299

Figure 31: Sales for Acute HF in Germany by Drug Class, 2025* 300

Figure 32: Sales for Chronic HF in Italy by Drug Class, 2015-2025 304

Figure 33: Sales for Acute HF in Italy by Drug Class, 2025* 305

Figure 34: Sales for Chronic HF in Spain by Drug Class, 2015-2025 309

Figure 35: Sales for Acute HF in Spain by Drug Class, 2025* 310

Figure 36: Sales for Chronic HF in the UK by Drug Class, 2015-2025 314

Figure 37: Sales for Acute HF in the UK by Drug Class, 2025* 315

Figure 38: Sales for Chronic HF in Japan by Drug Class, 2015-2025 319

Figure 39: Sales for Acute HF in Japan by Drug Class, 2015-2025 320

Additional Details

Publisher

Global Data

Publisher Information

Reference

27045 | GDHC127PIDR

Number of Pages

383

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023
PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023SummaryRenal cel...
21 Apr 2016 by Global Data USD $9,346 (normally
USD $10,995)
More Info
SAVE 15% today! PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024SummaryPsoriasis (PsO) is a...
13 Apr 2016 by Global Data USD $9,346 (normally
USD $10,995)
More Info
SAVE 15% today! PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024SummaryBipolar disor...
01 Mar 2016 by Global Data USD $9,346 (normally
USD $10,995)
More Info
SAVE 15% today! PharmaPoint: Hepatitis B Virus (HBV) Therapeutics - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Hepatitis B Virus (HBV) Therapeutics - Global Drug Forecast and Market Analysis to 2024...
01 Jan 2016 by Global Data USD $9,346 (normally
USD $10,995)
More Info
SAVE 15% today! PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024
PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024SummaryDry Eye Syn...
05 Nov 2015 by Global Data USD $9,346 (normally
USD $10,995)
More Info
SAVE 15% today! PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2024SummaryAlthough the...
03 Nov 2015 by Global Data USD $9,346 (normally
USD $10,995)
More Info
SAVE 15% today! PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023
PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023SummaryThe Multiple ...
01 Nov 2015 by Global Data USD $9,346 (normally
USD $10,995)
More Info
SAVE 15% today! PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024SummaryIn t...
01 Oct 2015 by Global Data USD $9,346 (normally
USD $10,995)
More Info
SAVE 15% today! PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024SummaryMultiple Sc...
10 Sep 2015 by Global Data USD $9,346 (normally
USD $10,995)
More Info
SAVE 15% today! PharmaPoint: Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024SummaryAllergic Rhi...
01 Sep 2015 by Global Data USD $9,346 (normally
USD $10,995)
More Info

This report is published by Global Data

Download Free Report Summary PDF

PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025 [Published by Global Data] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...